InnoVec Biotherapeutics Secures Tens of Millions in Series A+ Financing to Advance Gene Delivery Platform and Clinical Pipeline

On June 12, 2025, it was reported that InnoVec Biotherapeutics Inc. (hereinafter referred to as "Innovecbio"), recently completed a multi-million yuan A+ round of financing. This round of investment was led by Tianjin Venture Capital Management Co., Ltd., with participation from new investors and existing shareholders. The funds raised will mainly be used for the clinical validation and advancement of the company's product pipeline, as well as innovation in the gene delivery platform. This is reportedly one of the few financing events this year in the adeno-associated virus (AAV) gene therapy drug sector.

InnoVec Biotherapeutics Inc. is a clinical-stage gene therapy company driven by vector innovation. The company is committed to developing gene therapy delivery tools suitable for human use, addressing the challenges of translational difficulties from animals to humans in delivery tool development. Its goal is to find gene delivery tools for all tissues and organs, enabling gene therapy to be widely applied to both rare and common diseases. Innovecbio has highly efficient teams in technical development, pipeline research, process optimization, and clinical operations, establishing a leading technology development platform that covers multiple disease areas such as ophthalmology, neurology, and muscular diseases. Several innovative products have entered the IIT and IND stages.

Dr. Fan Tu, Managing Director of Tianjin Venture Capital Management Co., Ltd.It is believed that AAV is the most important vector form in the field of gene therapy, with great application prospects and advantages in both local and systemic administration. With China's engineering capabilities, it may be possible to make gene therapy, previously an overseas "astronomically priced drug," more affordable, truly benefiting a large number of patients with genetic diseases. Although large multinational pharmaceutical companies such as Pfizer, Vertex, and Takeda have abandoned their AAV gene therapy drug pipelines, other companies like Roche, Eli Lilly, and Novartis have introduced new AAV vector technologies. These events highlight the limitations of older AAV vectors in clinical applications and the strong demand for new AAV vectors in the clinic. Innovecbio (InnoVec Biotherapeutics Inc.) is one of the few enterprises in China with a research and development system for new AAV vectors, and it is expected to address broader clinical needs, becoming a leading enterprise in this field domestically and even internationally.

InnoVec Biotherapeutics Inc. is a clinical-stage gene therapy company driven by vector innovation. The company is committed to developing gene therapy delivery tools suitable for human use, addressing the challenges of translating delivery tools from animals to humans. Its goal is to find gene delivery tools for all tissues and organs, enabling gene therapy to be widely applied to both rare and common diseases. InnoVec Biotherapeutics boasts efficient teams in technology development, pipeline research, process optimization, and clinical operations. It has established a leading technology development platform covering multiple disease areas such as ophthalmology, neurology, and muscular diseases. Several innovative products have entered the IIT and IND stages.

Tianjin Venture Capital Management Co., Ltd. (hereinafter referred to as "Tianchuang Capital") was established in 2003. Relying on its deep industry accumulation and government background since the start of commercial operations, it is based in Tianjin and radiates throughout China. With twenty years of deep cultivation in the venture capital field, it has cumulatively managed a fund size of 10 billion yuan, invested in more than 160 technology-based enterprises, and nearly 20% of the invested enterprises have gone public.

Tianjin Venture Capital Management Co., Ltd. has successfully invested in companies such as Sugon, Hygon, VeriSilicon, Zhipu AI, Dark Side of the Moon, PieSky, and Yutai Micro in the information technology innovation sector; in the healthcare sector, it has successfully invested in companies like Asymchem, Baotai Biotech, Huahao Zhongtian, Red Sun Pharmaceutical, and Fenh Healthcare; in the intelligent manufacturing sector, it has successfully invested in companies such as Changrong Co., Ltd., Jianke Machinery, and Feixuan Technology; in the new energy and new materials sector, it has successfully invested in companies like Yihuatong, Rianlon, Kelin Electric, Jiuri New Materials, and Zhongtai Materials. In the future, Tianjin Venture Capital Management Co., Ltd. will focus precisely on sectors such as information technology innovation, healthcare, and intelligent manufacturing, empowering more outstanding companies to grow rapidly together with investors.